Key result
PCV2 subunit vaccine provides ~100% protection against viremia in piglets, driven by CD4+ T cells.
Why the study?
The cellular immune response against PCV2 and its interaction with vaccination is not fully understood, especially regarding antigen-specific T cell responses.
Does PCV2 subunit vaccination induce protective cytokine-producing T cell responses against PCV2 infection in piglets?
Does PCV2 subunit vaccination induce protective cytokine-producing T cell responses against PCV2 infection in piglets?
Absolute Event Rate: 0% vs 83.3%
PCV2 vaccination induces IFN-γ/TNF-α co-producing T cells, which may serve as a correlate of protection against viremia in pigs.
T cell profiling in PCV2 vaccination trials may guide swine vaccine optimization; leaves open the protective role of cellular immunity.
Porcine circovirus type 2 (PCV2) is one of the economically most important pathogens for swine production worldwide. Vaccination is a powerful tool to control porcine circovirus diseases (PCVD). However, it is not fully understood how PCV2 vaccination interacts with the porcine immune system. Especially knowledge on the cellular immune response against PCV2 is sparse. In this study we analysed antigen-specific T cell responses against PCV2 in a controlled vaccination and infection experiment. We focused on the ability of CD4(+) T cells to produce cytokines using multicolour flow cytometry (FCM). Vaccination with a PCV2 subunit vaccine (Ingelvac CircoFLEX®) induced PCV2-specific antibodies only in five out of 12 animals. Conversely, vaccine-antigen specific CD4(+) T cells which simultaneously produced IFN-γ and TNF-α and had a phenotype of central and effector memory T cells were detected in all vaccinated piglets. After challenge, seroconversion occurred earlier in vaccinated and infected pigs compared to the non-vaccinated, infected group. Vaccinated pigs were fully protected against viremia after subsequent challenge. Therefore, our data suggests that the induction of IFN-γ/TNF-α co-producing T cells by PCV2 vaccination may serve as a potential correlate of protection for this type of vaccine.
No takes yet. Share an insight, caveat, or question.
Koinig et al. (2015) studied Porcine circovirus type 2 (PCV2) infection (n=24). PCV2 subunit vaccine (Ingelvac CircoFLEX) vs. Non-vaccinated controls was evaluated on Viremia after PCV2 challenge. Vaccination with a PCV2 subunit vaccine induced IFN-γ/TNF-α co-producing CD4+ T cells and fully protected piglets against viremia following subsequent PCV2 challenge.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: